Epigenomics AG Performance
| EPGNYDelisted Stock | USD 9.56 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Epigenomics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Epigenomics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Epigenomics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | 961 K |
Epigenomics |
Epigenomics Relative Risk vs. Return Landscape
If you would invest (100.00) in Epigenomics AG on February 5, 2024 and sell it today you would earn a total of 100.00 from holding Epigenomics AG or generate -100.0% return on investment over 90 days. Epigenomics AG is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded otc stocks are less volatile than Epigenomics, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Epigenomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Epigenomics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Epigenomics AG, and traders can use it to determine the average amount a Epigenomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EPGNY |
Based on monthly moving average Epigenomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Epigenomics by adding Epigenomics to a well-diversified portfolio.
Epigenomics Fundamentals Growth
Epigenomics OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Epigenomics, and Epigenomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Epigenomics OTC Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 817.87 K | |||
| Price To Earning | (10.48) X | |||
| Price To Book | 0.53 X | |||
| Price To Sales | 13.79 X | |||
| Revenue | 6.2 M | |||
| EBITDA | (1.94 M) | |||
| Cash And Equivalents | 18.04 M | |||
| Cash Per Share | 5.51 X | |||
| Total Debt | 1.01 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 17.04 X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (1.49) X | |||
| Total Asset | 24.66 M | |||
| Retained Earnings | (69.31 M) | |||
| Current Asset | 10.99 M | |||
| Current Liabilities | 5.46 M | |||
About Epigenomics Performance
To evaluate Epigenomics AG OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Epigenomics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Epigenomics OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Epigenomics AG market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Epigenomics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 32 people.Things to note about Epigenomics AG performance evaluation
Checking the ongoing alerts about Epigenomics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Epigenomics AG help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Epigenomics AG is not yet fully synchronised with the market data | |
| Epigenomics AG has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 6.2 M. Net Loss for the year was (2.43 M) with profit before overhead, payroll, taxes, and interest of 6.07 M. | |
| Epigenomics AG has accumulated about 18.04 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51. |
- Analyzing Epigenomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Epigenomics' stock is overvalued or undervalued compared to its peers.
- Examining Epigenomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Epigenomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Epigenomics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Epigenomics' otc stock. These opinions can provide insight into Epigenomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Epigenomics OTC Stock
If you are still planning to invest in Epigenomics AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epigenomics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |